Step and Walking Pattern From Cardiac Monitor Study

NCT ID: NCT04971993

Last Updated: 2023-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-05

Study Completion Date

2023-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To understand the feasibility of characterizing walking patterns in heart failure subjects and subjects at risk for arrhythmias using an investigational wearable monitor called the SWAN study system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, feasibility study that will enroll up to 60 participants diagnosed with Class II (30-35%) or III (30-35%) heart failure or are indicated for an insertable cardiac monitor with no history of heart failure (30-35%).

There will be one study visit per participant and a follow up phone call. The study visit includes device placement and data collection during rest and during a 6 minute hall walk. The device will then be removed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure NYHA Class II Heart Failure NYHA Class III Insertable Cardiac Monitor

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

exercise walk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heart Failure NYHA Class II

Participants are diagnosed with NYHA Class II heart failure.

Wearable Cardiac Monitor

Intervention Type DEVICE

Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

Heart Failure NYHA Class III

Participants are diagnosed with NYHA Class III heart failure.

Wearable Cardiac Monitor

Intervention Type DEVICE

Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

At risk for arrythmias

Participants are indicated for an insertable cardiac monitor with no history of heart failure.

Wearable Cardiac Monitor

Intervention Type DEVICE

Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wearable Cardiac Monitor

Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 18 years or older
* Willing and capable to provide written informed consent and agrees to participate in all protocol required activities
* Subjects must meet one of the following criteria:
* Documented New York Heart Association (NYHA) class II or III heart failure within the last 6 months

OR

* Subjects that have a known heart condition (non-heart failure) and are at risk of developing an abnormal heart rhythm, or have symptoms that may suggest a cardiac arrhythmia such as dizziness, palpitations, syncope, chest pain and/or shortness of breath

Exclusion Criteria

* Not able to walk continuously for a period of 6 minutes at the subjects baseline walking speed
* Prior hospitalization or surgery that affects the subjects baseline walking speed at time of enrollment
* Cardiovascular event such as unstable angina or myocardial infarction that affects the subjects baseline walking speed at time of enrollment
* Subject is currently enrolled in another clinical trial (excluding registries) that may interfere with the placement of the study system
* Known allergy to materials used in the study (adhesive tape, titanium, ECG electrodes)
* Subject is pregnant as indicated by subject report and/or medical record at the time of enrollment
* Subjects with rash or open wound on torso locations where investigational devices will be placed
* Have an active implantable device
* Any past or current medical event that could represent a risk for the subject to perform the study required activities in the opinion of the investigator
* Any medical signs or symptoms that in the opinion of the investigator could represent a risk for the subject (I.e. increased baseline blood pressure or heart rate).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jamie Pelzel, MD

Role: PRINCIPAL_INVESTIGATOR

CentraCare Heart and Vascular Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CentraCare Heart and Vascular Clinic

Saint Cloud, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C2168

Identifier Type: -

Identifier Source: org_study_id